⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MDCX News
Medicus Pharma Ltd. Common Stock
Medicus Pharma on Bloomberg World
accessnewswire.com
MDCX
New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd.
accessnewswire.com
MDCX
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
globenewswire.com
MDCX
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony
accessnewswire.com
MDCX
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
globenewswire.com
MDCX
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
globenewswire.com
MDCX
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women
globenewswire.com
MDCX
Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates
globenewswire.com
MDCX
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
accessnewswire.com
MDCX
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
globenewswire.com
MDCX